valrubicin has been researched along with Carcinoma, Transitional Cell in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kamat, AM; Li, R; Spiess, PE | 1 |
Barlow, LJ; Benson, MC | 1 |
Bahnson, RR; Bamberger, MH; Bellingham, C; Childs, SJ; Edson, M; Giantonio, B; Greenberg, RE; Israel, M; O'Dwyer, PJ; Steinberg, GD; Sweatman, T; Wood, D | 1 |
Baselli, EC; Greenberg, RE | 1 |
Hetherington, J; Kisbenedek, L; Newling, DW; Robinson, MR; Sundaram, SK | 1 |
Luciani, LG; Murphy, WM; Neulander, E; Wajsman, Z | 1 |
Alsikafi, NF; Kuznetsov, DD; O'Connor, RC; Steinberg, GD | 1 |
3 review(s) available for valrubicin and Carcinoma, Transitional Cell
Article | Year |
---|---|
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Interferons; Mitomycin; Mycobacterium bovis; Neoplasm, Residual; Photochemotherapy; Photosensitizing Agents; Thiotepa; Urinary Bladder Neoplasms | 2000 |
Intravesical valrubicin in the treatment of carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Guidelines as Topic; Humans; Molecular Structure; Urinary Bladder Neoplasms | 2001 |
2 trial(s) available for valrubicin and Carcinoma, Transitional Cell
Article | Year |
---|---|
Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anthracyclines; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 1997 |
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2001 |
2 other study(ies) available for valrubicin and Carcinoma, Transitional Cell
Article | Year |
---|---|
Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?
Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystectomy; Doxorubicin; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Practice Guidelines as Topic; Urinary Bladder Neoplasms | 2018 |
Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Doxorubicin; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Treatment Outcome; Urinary Bladder Neoplasms | 2001 |